When prior available MAL and bcl-2 expression data are included in a multivariate analysis of all clinical and biologic factors, a FOXP3/GrB ratio of 1 or less and tumor cell expression of MAL and bcl-2 all independently predicted poor failure-free survival (FFS) [59]. The gene discussed is FOXP3; the disease is neoplasm.